ロード中...
Management of imatinib-resistant patients with chronic myeloid leukemia
Since its approval in 2001 for frontline management of chronic myelogenous leukemia (CML), imatinib has proven to be very effective in achieving high remission rates and improving prognosis. However, up to 33% of patients will not achieve optimal response. This has led researchers to develop new sec...
保存先:
| 主要な著者: | , , , , |
|---|---|
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
SAGE Publications
2013
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3629755/ https://ncbi.nlm.nih.gov/pubmed/23610618 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/2040620712468289 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|